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Objective. To assess hepatitis C virus (HCV) antibody prevalence in the EuroSIDA cohort, along with survival,
human immunodeficiency virus (HIV)–1 disease progression, virologic response (plasma HIV-1 RNA load of !500
copies/mL), and CD4 cell count recovery by HCV serostatus in patients initiating highly active antiretroviral
therapy (HAART).
Results. HCV serostatus at or before enrollment was available for 5957 patients; 1960 (33%) and 3997 (67%)
were HCV seropositive and seronegative, respectively. No association between an increased incidence of acquired
immunodeficiency syndrome-defining illnesses or death and HCV serostatus was seen after adjustment for other
prognostic risk factors known at baseline (adjusted incidence rate ratio [IRR], 0.97 [95% confidence interval {CI},
0.81–1.16]). However, there was a large increase in the incidence of liver disease–related deaths in HCV-seropositive
patients in adjusted models (IRR, 11.71 [95% CI, 6.42–21.34]). Among 2260 patients of known HCV serostatus
initiating HAART, after adjustment, there was no significant difference between HCV-seropositive and -seronegative
patients with respect to virologic response (relative hazard [RH], 1.13 [95% CI, 0.84–1.51]) and immunologic
response, whether measured as a 50% increase (RH, 0.94 [95% CI, 0.77–1.16]) or a 50 cells/mL increase (RH,
0.92 [95% CI, 0.77–1.11]) in CD4 cell count after HAART initiation.
Conclusions. HCV serostatus did not affect the risk of HIV-1 disease progression, but the risk of liver disease-
related deaths was markedly increased in HCV-seropositive patients. The overall virologic and immunologic re-
sponses to HAART were not affected by HCV serostatus.
Hepatitis C virus (HCV) coinfection has become one
of the most challenging clinical situations to manage
in HIV-1–infected individuals. Indeed, at present, end-
stage liver disease is the cause of 17%–45% of in-hos-
pital deaths in HIV-1–infected individuals in the West
[1–3]. Because of shared routes of transmission, an es-
timated 30% of HIV-1–infected individuals are coin-
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fected with HCV in the United States [4]. In Europe,
epidemiologic differences in the prevalence of HCV in-
fection have been described among countries, with rates
of HCV coinfection being 150% in Spain and Italy but
!15% in northern European countries, such as Ger-
many and Denmark [5].
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HIV-1 may accelerate HCV-related liver disease, especially
when HIV-1–associated immunodeficiency progresses [6, 7]. In
support of these observations, liver-biopsy studies have dem-
onstrated higher rates of cirrhosis and more-advanced fibrosis
stages in the livers of HIV-1/HCV–coinfected patients than of
HCV-monoinfected patients after comparable infection times
[8, 9]. However, these studies were conducted before the in-
troduction of highly active antiretroviral therapy (HAART) and,
hence, were not able to assess a possible influence of HAART
on the course of chronic HCV infection. Of interest, several
studies have suggested that HAART has a protective effect with
regard to the further development of liver fibrosis and liver
disease–related mortality in HIV-1/HCV–coinfected individuals
[10–12].
Studies evaluating the influence of HCV infection on HIV-
1 disease progression, however, have shown conflicting results.
Although some studies have demonstrated an association be-
tween HCV infection and faster HIV-1 disease progression (or
at least a poorer CD4 cell count response) in coinfected in-
dividuals receiving HAART [13–18], other studies have not
found such an association [19–22]. To clarify this controver-
sy, we examined the clinical outcome and the virologic and
immunologic responses to HAART in a large group of HIV-
1–infected patients in the EuroSIDA cohort, comparing pa-
tients with and without HCV coinfection.
PATIENTS, MATERIALS, AND METHODS
Patients. EuroSIDA is a prospective, European study of HIV-
1–infected patients at 89 centers across Europe, as well as Israel
and, now, Argentina; details of the study have been published
elsewhere [23]. Briefly, the centers provided data on consecutive
patients seen at the outpatient clinics beginning in May 1994
until a predefined number of patients was enrolled from each
center. The first group of 3117 patients was defined as Euro-
SIDA cohort I. Enrollment of a second cohort of 1365 patients
(cohort II) began in December 1995. In April 1997, a further
2844 patients were recruited and were defined as cohort III.
Cohort IV, which includes 1225 patients, was enrolled begin-
ning in April 1999; Cohort V, which includes 1258 patients,
was recruited beginning in September 2001; and cohort VI,
which includes 1420 patients, was recruited beginning in No-
vember 2003. For cohorts I–III, eligible patients were those
who had had a CD4 cell count !500 cells/mL during the previous
4 months. The CD4 cell count restriction was removed for
cohorts IV–VI.
At recruitment, in addition to demographic and clinical in-
formation, a complete antiretroviral history was obtained, to-
gether with the 8 most recent CD4 cell count and plasma HIV-
1 RNA load measurements. At each follow-up visit, details on
all CD4 cell counts and plasma HIV-1 RNA loads measured
since the last follow-up visit were obtained, as were the dates
of starting and stopping each antiretroviral drug received and
the use of drugs for prophylaxis against opportunistic infec-
tions. The dates of diagnosis of all AIDS-defining illnesses, in-
cluding those diagnosed subsequent to the first diagnosis of
such an illness, were also recorded, using the Centers for Dis-
ease Control and Prevention’s 1993 clinical definition of AIDS
[24]. Follow-up was conducted until the autumn of 2004.
HCV antibody testing was performed by use of commercial
ELISAs. Only limited numbers of HCV RNA load measure-
ments were performed in Europe and, thus, these data were
not routinely available.
Statistical methods. The patients were grouped at recruit-
ment by HCV serostatus—unknown, seronegative, or seropos-
itive. Those patients without prospective follow-up were ex-
cluded from all analyses. The characteristics of the patients with
and without known HCV serostatus were compared, as were
the characteristics of the patients who were known to be HCV
seropositive or seronegative at recruitment. Continuous vari-
ables were compared by the Wilcoxon rank sum test, and cat-
egorical variables were compared by the x2 test.
The incidence of clinical HIV-1 disease progression (defined
as a new AIDS-defining illness or death by any cause [hereafter,
“any death”]) was determined by dividing the number of clin-
ical events by the number of person-years of follow-up (PYFU).
The patients were followed either from their date of recruitment
into the EuroSIDA cohort or from their first HCV antibody
test result (baseline), whichever was later, to either their first
AIDS-defining illness or death. Thus, patients who had HCV
antibody testing results available after recruitment were in-
cluded in the analyses from the time of their first available
result. Patients with no clinical events were censored at the date
of their last follow-up visit. Poisson regression was used to
determine the incidence rate ratios (IRRs) of clinical events,
comparing HCV-seropositive and HCV-seronegative patients,
both in univariable analyses and after adjustment. In one set
of multivariable models, only baseline (i.e., fixed) factors were
included; in a second set, updated values (i.e., time dependent)
were included. Analyses were repeated with and without ad-
justment for plasma HIV-1 RNA load, because this variable was
available only in a smaller group of patients (routine viral load
testing was not introduced until 1997). Adjustments were made
for CD4 cell count, age, prior AIDS diagnosis, HIV-1 treatment
at baseline, baseline date, hepatitis B surface antigen (HBsAg)
status, sex, ethnicity, geographic region, and risk group. In the
updated-factors multivariable models, CD4 cell count and in-
itiation of HAART were adjusted for as time dependent, and,
where AIDS was not part of the end point, the models were
further adjusted for diagnosis of a new AIDS-defining illness.
HAART was defined as treatment with a protease inhibitor (PI),
nonnucleoside reverse transcriptase inhibitor (NNRTI), or aba-
cavir, with at least 2 other nucleoside analogues.
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For the analysis of predictors of time to virologic and im-
munologic responses, we used Cox proportional hazards models,
with stratification by center. A virologic response was defined as
achieving a plasma HIV-1 RNA load of !500 copies/mL after
initiation of HAART, and an immunologic response was defined
in 2 ways: (1) an increase of 50% in CD4 cell count after
initiation of HAART and (2) an increase of50 cells/mL in CD4
cell count after initiation of HAART. Patients who did not achieve
either response were censored at the date of their last plasma
HIV-1 RNA load or CD4 cell count measurement. No ad-
justments were made for changes to or stopping of the initial
HAART regimen. Models were adjusted for factors that have
been previously shown to be related to a virologic or immu-
nologic response, including CD4 cell count and plasma HIV-
1 RNA load at initiation of HAART, the HAART regimen in-
itiated, prior treatment, risk group, age, and prior diagnosis of
an AIDS-defining illness. Both CD4 cell count and plasma HIV-
1 RNA load were included as categorical variables, so that pa-
tients with missing data at initiation of HAART would be
included.
RESULTS
Demographics and characteristics of patients. The patients
of unknown HCV serostatus at recruitment were predomi-
nantly in the EuroSIDA cohorts recruited beginning in 1994
and 1995, before the implementation of routine HCV testing
across Europe. As a consequence, the patients of unknown HCV
serostatus at recruitment had lower CD4 cell counts, were more
likely to have AIDS, and were more likely to have initiated ART
as monotherapy or dual therapy at recruitment into the Euro-
SIDA cohort.
Table 1 summarizes the main clinical and demographic char-
acteristics of the patients of known HCV serostatus at recruit-
ment into the EuroSIDA cohort. Overall, 3997 (67%) were
HCV seronegative, and 1960 (33%) were HCV seropositive. Of
the HCV-seropositive patients, 78% had been infected with
HIV-1 via injection drug use—and, hence, probably also ac-
quired HCV via this route—and 31% were female (compared
with 23% of the HCV-seronegative patients [ ]). InP ! .0001
contrast, in the HCV-seronegative patients, HIV-1 transmis-
sion was mostly related to sexual contact. Although the differ-
ences were statistically significant because of the large sample
size, the HCV-seropositive patients were broadly comparable
to the HCV-seronegative patients with respect to plasma HIV-
1 RNA load at recruitment (median, 3.21 log copies/mL [in-
terquartile range {IQR}, 2.19–4.40 log copies/mL] vs. 2.87 log
copies/mL [IQR, 1.90–4.28 log copies/mL]; ) andPp .0020
CD4 cell count at recruitment (median, 291 cells/mL [IQR, 160–
441 cells/mL] vs. 305 cells/mL [IQR, 170–455 cells/mL]; Pp
). In addition, there was a higher proportion of patients.035
with AIDS before or at recruitment into the EuroSIDA co-
hort in the HCV-seronegative group versus the HCV-seroposi-
tive group (27% vs. 21%; ). A small number of patientsP ! .0001
had alanine aminotransferase (ALT) or aspartate aminotransfer-
ase (AST) levels measured before or at recruitment into the
EuroSIDA cohort, and, as was expected, elevated ALT and AST
levels were more frequent in the HCV-seropositive group than
they were in the HCV-seronegative group ( ). ChronicP ! .0001
hepatitis B (positivity for serum HBsAg) was more frequent in
the HCV-seropositive group than it was in the HCV-seronegative
group (9% vs. 7%; ). Treatment for HCV infection wasP ! .0001
uncommon in the HCV-seropositive patients (2%). There were
large variations in rates of HCV seropositivity between Europe
regions as well as within the regions (table 2).
Clinical progression. Overall, 917 new AIDS-defining ill-
nesses, 819 any deaths, 109 liver disease–related deaths, and 462
non–HIV-1–related deaths occurred in the patients of known
HCV serostatus (table 3). The event rates of all of the end points
considered were significantly higher in the HCV-seropositive pa-
tients than they were in the HCV-seronegative patients.
However, the event rates shown in table 3 may be confounded
by other factors that affect the outcomes assessed. Table 4 sum-
marizes the IRRs by HCV serostatus in both univariable and
multivariable analyses. The multivariable models are shown sep-
arately after adjustment for (1) fixed factors known at baseline
and (2) updated factors for CD4 cell count, initiation of HAART,
and, where AIDS was not part of the end point, diagnosis of a
new AIDS-defining illness. It is noteworthy that, although the
univariable analysis showed a higher incidence of a new AIDS-
defining illness or any death in the HCV-seropositive patients
than in the HCV-seronegative patients (IRR, 1.44 [95% confi-
dence interval {CI}, 1.29–1.60]; ]), no increased inci-P ! .0001
dence of new AIDS-defining illnesses or any deaths was found
in the HCV-seropositive patients after adjustment for either base-
line factors (IRR, 0.97 [95% CI, 0.81–1.16]; ) or updatedPp .72
factors (IRR, 1.06 [95% CI, 0.89–1.28]; ).Pp .50
In addition, compared with the HCV-seronegative patients,
the HCV-seropositive patients had a significantly decreased in-
cidence of AIDS-defining illnesses after adjustment. However,
they had a significantly increased incidence of any death in both
the fixed-factor and the updated-factor multivariable models
(IRR, 1.41 and 1.80; and , respectively), thePp .0024 P ! .0001
result of a 110-fold higher incidence of liver disease–related
deaths in the HCV-seropositive patients in the fixed-factor mul-
tivariable model (IRR, 11.71 [95% CI, 6.42–21.34]; )P ! .0001
and an even higher incidence in the updated-factor multivar-
iable model (IRR, 12.31 [95% CI, 6.77–22.41]; ).P ! .0001
All of the analyses shown in table 4 were repeated with ad-
ditional adjustment for plasma HIV-1 RNA load either as a
fixed factor at baseline or as an updated factor. The results were
similar (data not shown). In addition, all univariable and mul-
tivariable analyses were repeated separately for injection drug
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Table 1. Characteristics of the study population, by hepatitis C virus (HCV) serostatus at re-
cruitment into the EuroSIDA cohort.
Characteristic
HCV
seronegative
HCV
seropositive P a
Patients 3997 (67.1) 1960 (32.9) …
Sex !.0001
Male 3083 (77.1) 1358 (69.3)
Female 914 (22.9) 602 (30.7)
Age, median (IQR), years 37.5 (31.8–45.4) 33.9 (29.4–39.0) !.0001
Ethnicity !.0001
White 3464 (86.7) 1840 (93.9)
Other 533 (13.3) 120 (6.1)
Geographic region !.0001
Southern Europe/Argentina/Israel 982 (24.6) 695 (35.5)
Central Europe 1137 (28.5) 293 (15.0)
Northern Europe 1186 (29.7) 359 (18.3)
Eastern Europe 692 (17.3) 613 (31.3)
Mode of HIV-1 acquisition !.0001
Homosexual contact 2139 (53.5) 129 (6.6)
Injection drug use 129 (3.2) 1519 (77.5)
Heterosexual contact 1443 (36.1) 200 (10.2)
Other 286 (7.2) 112 (5.7)
Prior AIDS diagnosis 1084 (27.1) 420 (21.4) …
HIV-1 treatment at recruitment !.0001
Naive 690 (16.8) 492 (25.1)
ART 1203 (30.1) 754 (38.5)
HAART 2124 (53.1) 714 (36.4)
Plasma HIV-1 RNA load at recruitment
Data available 3145 (78.7) 1182 (60.3) !.0001
!500 copies/mL 1424 (45.3) 468 (39.6) .0080
Median (IQR), log copies/mL 2.87 (1.90–4.28) 3.21 (2.19–4.40) .0020
CD4 cell count at recruitment
!50 cells/mL 318 (8.0) 187 (9.5) .039
Median (IQR), cells/mL 305 (170–455) 291 (160–441) .035
Hepatitisb
Increased ALT level 639 (55.7) 368 (82.7) !.0001
Increased AST level 795 (76.4) 446 (92.5) !.0001
HBsAg status !.0001
Negative 3434 (85.9) 1552 (79.2)
Positive 281 (7.0) 177 (9.0)
Unknown 282 (7.1) 231 (118.8)
Duration of follow-up, median (IQR), months 45 (15–84) 32 (9–84) .0032
NOTE. Data are no. (%) of patients, unless otherwise noted. Forty-six HCV-seropositive patients (2.3%) had
received treatment of any kind for HCV infection. HAART, highly active antiretroviral therapy; HBsAg, hepatitis B surface
antigen; IQR, interquartile range.
a For the comparison between the HCV-seronegative patients and the HCV-seropositive patients.
b Alanine aminotransferase (ALT) levels at recruitment were available for 1593 patients and were classified as
increased when they reached 123 U/L for men and 119 U/L for women, and aspartate aminotransferase (AST) levels
at recruitment were available for 1522 patients and were classified as increased when they reached 119 U/L for men
and 115 U/L for women.
users (IDUs) and other risk groups. Among IDUs, after ad-
justment for fixed factors, there was a significantly increased
incidence of liver disease–related deaths (IRR, 12.66 [95% CI,
6.76–23.71]; ) in those coinfected with HIV-1 andP ! .0001
HCV. A similar trend, although smaller in size and not sig-
nificant, was observed among non-IDUs (IRR, 6.16 [95% CI,
0.85–44.50]; ). However, it should be noted that thisPp .072
analysis had limited power, as is indicated by the wide CIs;
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Table 2. Distribution of rates of hepatitis C virus (HCV) seropositivity among patients of known HCV serostatus
at recruitment into the EuroSIDA cohort.
Geographic region, country
Patients of known
HCV serostatus
IDUs of known
HCV serostatus
HCV-seropositive
patients who
acquired HIV-1
via injection
drug use, %Total no.
HCV
seropositive, % Total no.
HCV
seropositive, %
Southern Europe
Italy 743 56.9 373 95.7 84.4
Spain 249 53.0 109 90.8 75.0
Portugal 270 30.4 80 83.8 81.7
Greece 147 5.4 5 80.0 50.0
Central Europe
Switzerland 188 39.4 70 97.1 94.4
France 496 21.6 66 83.3 51.4
Germany 736 15.6 84 82.1 60.0
Austria 26 15.4 9 44.4 100.0
Luxembourg 88 12.5 7 100.0 63.6
Belgium 87 11.5 4 100.0 40.0
Northern Europe
Denmark 357 19.9 46 97.8 63.4
The Netherlands 49 20.4 4 100.0 40.0
United Kingdom 526 24.5 121 88.4 82.9
Ireland 85 36.5 30 93.3 90.3
Sweden 205 29.3 47 93.6 73.3
Norway 132 22.7 27 88.9 80.0
Eastern Europe
Hungary 78 3.9 0 0 0
Czech Republic 59 17.0 5 80.0 40.0
Slovakia 33 3.0 1 100.0 100.0
Poland 484 61.2 255 96.1 82.8
Estonia 80 56.3 38 94.7 80.0
Lithuania 80 51.3 39 94.9 90.2
Rumania 107 3.7 0 0 0
Ukraine 122 71.3 82 97.6 92.0
Serbia and Montenegro 29 24.1 5 80.0 57.1
Latvia 93 66.7 64 87.5 90.3
Belarus 47 70.2 31 96.8 90.9
Russia 93 25.8 17 100.0 70.8
South America, Argentina 152 29.0 24 79.2 43.2
Middle East, Israel 116 5.2 7 71.4 83.3
NOTE. IDU, injection drug user.
there were 67 liver disease–related deaths during 8037 PYFU
in IDUs and 42 liver disease–related deaths during 24,084 PYFU
in non-IDUs ( ).P ! .0001
Effect of HAART by HCV serostatus. A total of 3760 pa-
tients from the entire EuroSIDA cohort initiated HAART after
enrollment into the study and had some prospective follow-
up; of these, 2260 were of known HCV serostatus before ini-
tiation of HAART (66% were HCV seronegative and 34% were
HCV seropositive). There were no differences between the HCV-
seropositive patients and the HCV-seronegative patients with
respect to either CD4 cell count (median, 215 vs. 232 cells/mL;
) or plasma HIV-1 RNA load (median, 4.25 vs. 4.26Pp .22
log copies/mL; ) at the time when HAART was initi-Pp .45
ated. The groups were also comparable with respect to the
HAART regimen initiated: of the HCV-seropositive patients
and the HCV-seronegative patients, 70% in each group initiat-
ed a single PI–containing regimen; 15% and 14%, respectively,
initiated a dual PI–containing regimen; and 7% and 6%, re-
spectively, initiated an NNRTI-containing regimen ( ;Pp .083
x2 test).
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Table 3. Clinical events and event rates, by hepatitis C virus (HCV) serostatus.
Clinical event, HCV serostatus No. of events PYFU
No. of events/100
PYFU (95% CI) P
New AIDS-defining illness/any death !.0001
Seronegative 818 20,293 4.0 (3.8–4.3)
Seropositive 520 8989 5.8 (5.3–6.3)
New AIDS-defining illness .024
Seronegative 603 20,293 3.0 (2.7–3.2)
Seropositive 314 8989 3.5 (3.1–3.9)
Any death !.0001
Seronegative 456 22,221 2.1 (1.9–2.2)
Seropositive 363 9872 3.7 (3.3–4.1)
Liver disease–related death !.0001
Seronegative 20 22,221 0.1 (0.1–0.1)
Seropositive 89 9872 0.9 (0.7–1.1)
Non–HIV-1–related death !.0001
Seronegative 233 22,221 1.0 (0.9–1.2)
Seropositive 229 9872 2.3 (2.0–2.6)
NOTE. Person-years of follow-up (PYFU) and clinical events were allocated by current HCV serostatus. CI, con-
fidence interval.
Of the 2015 patients with a plasma HIV-1 RNA load of500
copies/mL or with an unknown viral load, 1799 (89%) achieved
a plasma HIV-1 RNA load of !500 copies/mL after initiation
of HAART (89% of the HCV-seronegative patients and 91%
of the HCV-seropositive patients) ( ; x2 test). The timePp .20
to first achieving a plasma HIV-1 RNA load of !500 copies/
mL was also comparable between the 2 groups (figure 1), be-
ing, on average, 5 months (95% CI, 5–6 months) for the
HCV-seronegative patients and 6 months (95% CI, 5–7 months)
for the HCV-seropositive patients ( ; log-rank test). SixPp .99
months after HAART initiation, 55% (95% CI, 52%–57%) of
the HCV-seronegative patients and 51% (95% CI, 47%–54%) of
the HCV-seropositive patients were estimated to have a plasma
HIV-1 RNA load of !500 copies/mL. After adjustment for rel-
evant variables, there was no significantly decreased frequency
of virologic response (plasma HIV-1 RNA load of !500 copies/
mL) in the HCV-seropositive patients, compared with that in
the HCV-seronegative patients (relative hazard [RH], 1.13 [95%
CI, 0.84–1.51]; ). Models that excluded patients withPp .42
missing viral loads at HAART initiation showed very similar
results (RH, 1.07 [95% CI, 0.88–1.30]; ). Of the 1518Pp .49
patients with a known plasma HIV-1 RNA load of500 copies/
mL at HAART initiation, 502 (33%) responded with a 50%
decrease in plasma HIV-1 RNA load. There was no difference
between the HCV-seropositive patients and the HCV-seronega-
tive patients with respect to this proportion (33%, for both
groups; ), and, after adjustment, there was no differencePp .99
in the RH of this end point between the HCV-seropositive pa-
tients and the HCV-seronegative patients (RH, 0.98 [95% CI,
0.78–1.22]; ).Pp .83
Of the 2215 patients with a known CD4 cell count at HAART
initiation, 1823 (82%) achieved a 50% increase in CD4 cell
count (83% of the HCV-seronegative patients and 80% of the
HCV-seropositive patients ( ; x2 test). The time to im-Pp .093
munologic success was not significantly different between the
2 groups (figure 2A); the median time to attaining the im-
munologic-success criteria was 9 months (95% CI, 8–9 months)
for the HCV-seronegative patients and was 9 months (95% CI,
8–10 months) for the HCV-seropositive patients ( ;Pp .067
log-rank test). A total of 2015 patients (91%) achieved a 50
cell/mL increase in CD4 cell count after initiation of HAART
(91% of the HCV-seronegative patients and 90% of the HCV-
seropositive patients) ( ; x2 test). The time to immu-Pp .33
nologic success was not significantly different between the 2
groups (figure 2B); the median time to attaining the immu-
nologic-success criteria was 6 months (95% CI, 5–6 months)
for the HCV-seronegative patients and was 6 months (95% CI,
5–6 months) for the HCV-seropositive patients ( ; log-Pp .056
rank test). After adjustment for relevant variables, there was
no significantly decreased frequency of immunologic response,
whether measured as a 50% increase (RH, 0.94 [95% CI,
0.77–1.16]; ) or as a 50 cells/mL increase (RH, 0.92Pp .58
[95% CI, 0.77–1.11]; ) in CD4 cell count after initiationPp .40
of HAART, in the HCV-seropositive patients versus the HCV-
seronegative patients. Further analyses that considered the change
in CD4 cell count at 6 months after initiation of HAART also
revealed no difference in immunologic response between the
2 groups.
DISCUSSION
Of the 5957 patients in the EuroSIDA cohort for whom HCV
serostatus at recruitment was known, 33% were HCV seropos-
itive. Given that ∼85% of individuals positive for HCV antibod-
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Table 4. Incidence rate ratios (IRRs), by hepatitis C virus (HCV) serostatus.
Clinical event, HCV serostatus
Univariable
Multivariable
Fixed factors Updated factors
IRR (95% CI) P IRR (95% CI) P IRR (95% CI) P
New AIDS-defining illness/any death !.0001 .72 .50
Seronegative 1.00 1.00 1.00
Seropositive 1.44 (1.29–1.60) 0.97 (0.81–1.16) 1.06 (0.89–1.28)
New AIDS-defining illness .020 .0016 .030
Seronegative 1.00 1.00 1.00
Seropositive 1.18 (1.03–1.35) 0.70 (0.56–0.87) 0.78 (0.62–0.98)
Any death !.0001 .0024 !.0001
Seronegative 1.00 1.00 1.00
Seropositive 1.79 (1.56–2.06) 1.41 (1.13–1.76) 1.80 (1.44–2.25)
Liver disease–related death !.0001 !.0001 !.0001
Seronegative 1.00 1.00 1.00
Seropositive 10.02 (6.17–16.27) 11.71 (6.42–21.34) 12.31 (6.77–22.41)
Non–HIV-1–related death … … !.0001
Seronegative 1.00 1.00 1.00
Seropositive 2.21 … …
NOTE. Fixed-factor multivariable models were adjusted for CD4 cell count, age, prior AIDS diagnosis, HIV-1 treatment at baseline, baseline date, hepatitis
B surface antigen status, sex, ethnicity, geographic region, and risk group. In the updated-factors multivariable models, CD4 cell count and initiation of highly
active antiretroviral therapy were adjusted for as time dependant and, where AIDS was not part of the end point, the models were further adjusted for diagnosis
of a new AIDS-defining illness.
ies are chronically infected with HCV [25], our results under-
score the clinical importance of concomitant HCV coinfection
in HIV-1–infected individuals in Europe. The problem is par-
ticularly worrisome in eastern and southern Europe, where HCV
coinfection rates are ∼50%. However, IDUs are more likely to
be tested for HCV than are non-IDUs, suggesting that the per-
centage of IDUs who test positive for HCV may be higher than
the overall prevalence of HCV infection. Indeed, in the present
study, there was little variation in rates of HCV seropositivity
among IDUs with known HIV-1 infection from all participating
countries, with 70%–100% of them being HCV coinfected.
As a limitation of our study, !10% of the HCV-seropositive
patients had had HCV RNA loads measured (data not shown),
preventing a direct comparison between patients with viremia
and those with self-limited HCV infection. However, hepatitis
C–associated viral clearance appears to be reduced in patients
coinfected with HIV-1 [25], whereas it remains unknown
whether HAART affects the rate of clearance of HCV. In ad-
dition, we did not include information on treatment for hep-
atitis C in our analyses. Treatment was uncommon, and neither
exclusion of patients receiving treatment nor adjustment for
treatment altered any of our findings (data not shown). Anoth-
er limitation of the present study is the fact that serologic results
were not available for all patients in the EuroSIDA cohort,
primarily because testing for HCV antibodies had not been
routinely introduced across Europe at the time when the study
began. It is possible that patients with more-advanced HCV-
associated disease died before they could be tested for HCV
and were, therefore, excluded from the present analyses. An
analysis limited to the patients recruited into cohort III and
later cohorts, however, revealed an HCV seroprevalence similar
to that found in the overall EuroSIDA cohort as well as similar
results throughout (data not shown). This limitation would not
affect the assessment of responses to HAART, which was in-
troduced around the time when HCV testing became common.
Finally, neither genotype data nor sufficient records on ALT
and AST levels were available, which would have allowed fur-
ther subanalysis in specific patient groups.
Overall, no increased risk of clinical progression to AIDS or
death could be found in the HCV-seropositive versus the HCV-
seronegative patients. Surprisingly, the HCV-seropositive pa-
tients even had a reduced incidence of new AIDS-defining ill-
nesses in the multivariable analyses; however, non–HIV-1–re-
lated deaths and liver disease–related deaths were significantly
more frequent in the HCV-seropositive patients, suggesting that
competing risks led to the observed reduction in AIDS inci-
dence. With better treatment options for HIV-1 infection and
an extended duration of HCV infection, coinfected patients
obviously become more prone to liver disease. The greater num-
ber of non–HIV-1–related deaths among the HCV-seropositive
patients may reflect comorbidity from continued active injec-
tion drug use in this group or from alcohol use. However, no
data on these matters have been collected, thereby preventing
further conclusions. In addition, in a further subanalysis, no
increase in clinical progression to AIDS was found in the HCV-
seropositive IDUs with HIV-1 coinfection, compared with that
in the HCV-seropositive IDUs without HIV-1 coinfection. These
results are in disagreement with those of the Swiss HIV Cohort
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Figure 1. Kaplan-Meier curve showing time to achieving a plasma HIV-1 RNA load of !500 copies/mL after initiation of highly active antiretroviral
therapy (HAART), by hepatitis C virus (HCV) serostatus when HAART was initiated.
Study, which showed an independent association between hep-
atitis C and HIV-1 disease progression and survival, especially
in HIV-1/HCV–coinfected IDUs [13]. In contrast, other studies
[19, 26] have reported no increased risk of the development
of a new AIDS-defining illness in HCV/HIV-1–coinfected per-
sons, once adjustments are made for receipt of HAART and
failure to suppress HIV-1 replication. The reason for these dis-
crepancies remain unclear but may be related to demographic
differences in the populations studied and the inclusion criteria
employed. For instance, the Swiss HIV Cohort Study included
only patients receiving HAART [13]. At baseline, there were
more patients with prior AIDS, lower CD4 cell counts, and
higher plasma viremia in the coinfected group than in the HCV-
negative group. The Johns Hopkins cohort, on the other hand,
included both treated and untreated individuals [19]. Moreover,
differences in duration of HCV infection might play a role.
In the EuroSIDA cohort, we also observed a higher rate of
liver disease–related deaths in the HCV-seropositive patients
than in the HCV-seronegative patients, but we did not observe
a higher rate of opportunistic infections. It should be high-
lighted, however, that the proportion of all deaths attributable
to liver disease in those with hepatitis C remains quite small.
Recent studies have suggested that a change occurs in the nat-
ural course of hepatitis C in HIV-1–infected patients after
HAART initiation, showing a better liver disease–related out-
come in coinfected patients receiving HAART [10–12].
Similar to what was observed in the Johns Hopkins cohort,
the HCV-seropositive patients in the EuroSIDA cohort were
more likely to be treatment naive and less likely to initiate
HAART than were the HCV-seronegative patients. In addition,
the HCV-seropositive patients were more likely to have received
prior monotherapy or double-nucleoside therapy, again reflect-
ing the difficulties of treatment in HIV-1/HCV–coinfected in-
dividuals in combination with the comorbidity and problems
associated with injection drug use. Possible differences in the
time point of HAART initiation as well as in the initial treat-
ment choices may also have affected the different outcomes in
the various cohort studies. Moreover, many factors—such as
treatment adherence, temporal changes in the way HAART is
used, better management of toxicities, and more awareness of
liver problems as people live longer—that cannot be measured
directly and that, therefore, were either incompletely assessed
or not assessed at all in the various cohort studies may also
have influenced the outcomes.
Subanalyses within our study examining virologic control in
patients initiating their first HAART regimen showed no dif-
ferences in the percentage of patients achieving as well as in
the time to achieve a plasma HIV-1 RNA load of !500 copies/
mL between the HCV-seropositive patients and the HCV-se-
ronegative patients. In the Swiss HIV Cohort Study [13], dif-
ferences in neither the virologic response to HAART nor the
virologic failure rate were observed in association with HCV
status. However, the study did find a lower CD4 cell count
recovery in HCV-positive patients receiving HAART than in
HCV-negative patients receiving HAART. This finding was not
confirmed in the present study, whether we defined immu-
nologic success as a CD4 cell count increase of 50% or of
50 cells/mL from baseline. A more-recent report from the
Swiss HIV Cohort Study, however, mentions that an extend-
ed follow-up of their patients (up to 4 years) resulted in a
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Figure 2. A, Kaplan-Meier curve showing time to achieving a 50% increase in CD4 cell count after initiation of highly active antiretroviral
therapy (HAART), by hepatitis C virus (HCV) serostatus when HAART was initiated. B, Kaplan-Meier curve showing time to achieving a 50 cells/
mL increase in CD4 cell count after initiation of HAART, by HCV serostatus when HAART was initiated.
finding of a lack of association between HCV status and im-
munologic recovery after initiation of HAART [27].
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